Vernalis plc (LON:VER) had its price objective lowered by equities researchers at Stifel Nicolaus from GBX 24 ($0.32) to GBX 21 ($0.28) in a research report issued to clients and investors on Monday. The firm presently has a “hold” rating on the stock. Stifel Nicolaus’ price target would indicate a potential upside of 10.53% from the company’s current price.

Several other analysts have also recently commented on VER. Panmure Gordon cut shares of Vernalis plc to a “hold” rating and set a GBX 65 ($0.86) target price for the company. in a research report on Friday, April 21st. Numis Securities Ltd reiterated an “add” rating and set a GBX 29 ($0.38) target price on shares of Vernalis plc in a research report on Friday, April 21st. N+1 Singer reiterated a “hold” rating and set a GBX 28 ($0.37) target price on shares of Vernalis plc in a research report on Friday, April 21st. Finally, RX Securities reiterated a “buy” rating on shares of Vernalis plc in a research report on Monday. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of GBX 39.40 ($0.52).

Shares of Vernalis plc (VER) traded down 10.53% during trading on Monday, hitting GBX 17.00. The company had a trading volume of 143,567 shares. The stock’s market cap is GBX 89.48 million. Vernalis plc has a 12-month low of GBX 16.00 and a 12-month high of GBX 49.75. The firm has a 50 day moving average of GBX 18.15 and a 200 day moving average of GBX 22.70.

TRADEMARK VIOLATION NOTICE: “Vernalis plc (VER) Price Target Lowered to GBX 21 at Stifel Nicolaus” was first posted by American Banking News and is owned by of American Banking News. If you are reading this piece on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The original version of this piece can be read at

Vernalis plc Company Profile

Vernalis plc is a commercial-stage pharmaceutical company. The Company is engaged in the research, development and commercialization of pharmaceutical products. The Company operates through two segments: Commercial, which covers all areas relating to the commercial sale of pharmaceutical products, the manufacture and distribution directly related to that activity, and Research and Development, which includes all activities related to the research and development of pharmaceutical products for a range of medical disorders.

Analyst Recommendations for Vernalis plc (LON:VER)

Receive News & Ratings for Vernalis plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vernalis plc and related companies with's FREE daily email newsletter.